Cell Therapy Phase 2 Licensing Benchmarks
Deal economics across 5 transactions with 4 disclosed upfront payments. Primary-source-verified from SEC EDGAR, FTC filings, and direct research.
Median Upfront
$136M
4 deals with terms
Median Total Value
$999M
Upfront + milestones
Royalty Range
9.5%--19%
Average low--high
Deal Count
5
2019--2024
The median upfront payment for phase 2 cell therapy licensing deals is $136M, based on 4 deals with disclosed terms from 2019--2024. Total deal values (including milestones) reach a median of $999M. Royalty rates typically range from 9.5% to 19%. All data is primary-source-verified from SEC EDGAR, FTC pre-merger filings, and company press releases.
Representative Transactions
| Licensor | Licensee | Year | Upfront | Total Value |
|---|---|---|---|---|
| Kite Pharma | Gilead Sciences | 2019 | $11.9B | $11.9B |
| Immatics | Bayer | 2019 | $158M | $1.2B |
| CRISPR Therapeutics | Vertex | 2022 | $115M | $812.414244M |
Showing 3 of 4 deals with disclosed terms. Full comp set available in the report.
Full cell-therapy phase-2 Comp Set
Get the complete analysis -- 4 deals with upfronts, milestones, royalties, and term structures.
Primary-source-verified from SEC EDGAR, FTC filings, and direct research
Run Your Own Analysis
Get a customized deal estimate for your specific cell therapy asset with our proprietary calculator.
Start CalculatingMethodology
This analysis draws from the Ambrosia Ventures proprietary deal database (1,600+ verified biopharma transactions, 2019--2024). All deal terms are primary-source-verified from SEC EDGAR (10-K, 10-Q, 8-K filings), FTC pre-merger notifications, FDA Orange Book, and company press releases. No secondary-source or scraped data is included. Medians are calculated from deals with disclosed financial terms only.